Plasma testosterone in patients receiving diethylstilbestrol

Phillip H. Beck, Jack W. McAninch, James L. Goebel, Ray E. Stutzman

Research output: Contribution to journalArticlepeer-review

Abstract

With accurate, inexpensive plasma testosterone assays now available it is possible to monitor the efficacy of hormonal manipulation in the patient with adenocarcinoma of the prostate. We monitored plasma testosterone in our patients receiving diethylstilbestrol (DES) 1 mg. per day. We found no statistical difference in mean plasma testosterone between patients with adenocarcinoma of the prostate and castrated patients with prostatic carcinoma, all receiving DES, 1 mg. per day. We recommend that plasma testosterone be closely monitored in patients receiving hormonal therapy for adenocarcinoma of the prostate.

Original languageEnglish (US)
Pages (from-to)157-160
Number of pages4
JournalUrology
Volume11
Issue number2
DOIs
StatePublished - Feb 1978
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Plasma testosterone in patients receiving diethylstilbestrol'. Together they form a unique fingerprint.

Cite this